|Home | About | Journals | Submit | Contact Us | Français|
Endocytic trafficking plays an important role in the regulation of the epidermal growth factor receptor (EGFR). To address if cellular kinases regulate EGFR internalization, we used anisomycin, a potent activator of kinase cascades in mammalian cells, especially the stress-activated mitogen-activated protein (MAP) kinase subtypes. Here, we report that activation of p38 MAP kinase by anisomycin is sufficient to induce internalization of EGFR. Anisomycin and EGF employ different mechanisms to promote EGFR endocytosis as anisomycin-induced internalization does not require tyrosine kinase activity or ubiquitination of the receptor. In addition, anisomycin treatment did not result in delivery and degradation of EGFR at lysosomes. Incubation with a specific inhibitor of p38, or depletion of endogenous p38 by small interfering RNAs, abolished anisomycin-induced internalization of EGFR while having no effect on transferrin endocytosis, indicating that the effect of p38 activation on EGFR endocytosis is specific. Interestingly, inhibition of p38 activation also abolished endocytosis of EGFR induced by UV radiation. Our results reveal a novel role for p38 in the regulation of EGFR endocytosis and suggest that stimulation of EGFR internalization by p38 might represent a general mechanism to prevent generation of proliferative or anti-apoptotic signals under stress conditions.
Growth factors and their transmembrane receptor tyrosine kinases (RTK) play important roles during embryonic development and in the regulation of several cellular processes including proliferation, survival, migration and differentiation (1, 2). Binding of growth factors to their receptors activates a myriad of signaling pathways that permit cells to respond to changes in the environment (3). In many cases, the termination of these signaling events is mediated by receptor internalization and degradation (4). The epidermal growth factor receptor (EGFR) is considered the prototypical member of the RTK family, and its activation and trafficking have been exhaustively characterized. Ligand binding results in receptor dimerization (5), activation and autophosphorylation of tyrosine residues in the cytosolic tail (6). Phosphotyrosines serve then as docking sites for the formation of protein networks that mediate signaling as well as receptor endocytosis and degradation (7). For example, autophosphorylation of specific tyrosines (Y992, Y1045, Y1068 and Y1086) is known to recruit specific adaptors such as phospholipase Cγ, Casitas B-lineage lymphoma (Cbl) or growth factor receptor binding protein 2 (Grb2).
Monoubiquitination of EGFR at multiple sites also seems to play an important role in receptor down-regulation (8). At the plasma membrane, receptor activation promotes the recruitment of Cbl, an ubiquitin ligase that mediates the ubiquitination of EGFR (9). Cbl can also interact with the endocytic machinery, thus ensuring EGFR internalization (10). At the endosomes, ubiquitin acts as a targeting signal for degradation through interaction with the multivesicular body-sorting machinery (11, 12).
However, there are still several aspects of EGFR trafficking that remain controversial. One is whether receptor ubiquitination is required for internalization or if it just plays a role in the delivery of the receptor to lysosomes. It has been shown that chimerae consisting of the extracellular and transmembrane domains of EGFR fused to a single cytosolic exposed ubiquitin are constitutively internalized and degraded (8, 12). However, other investigators have reported that receptor ubiquitination is not sufficient for EGFR endocytosis and that the role of Cbl is to link EGFR to coated pits through the interaction of Cbl with CIN85/endophilin complex (10, 13). Recently, it has been suggested that ubiquitin could determine the route of EGFR internalization so that non-ubiquitinated EGFR exclusively follows a clathrin-dependent pathway, while ubiquitinated EGFR can enter into the cell through both clathrin-coated pits and caveolae (14, 15).
Another open question to be resolved is the role of kinases in RTK internalization. As mentioned previously, EGF stimulation activates different protein kinases that participate in the transmission of many proliferative and differentiative signals. These protein kinases include the extracellular signal-regulated protein kinases (ERK) and two mitogen-activated protein (MAP) kinases, the c-Jun N-terminal kinase (JNK) (16) and the p38 MAP kinase (p38) (17). There is growing evidence showing that kinase activation does not only happen at the plasma membrane but also at endosomes. Several EGFR downstream signaling factors such as Grb2, Shc and mSOS localize to endosomes shortly after EGFR internalization (18, 19). In addition, robust MAP kinase activation requires the presence of active EGFR at endosomes (20, 21) and seems to promote cell survival (22, 23). Therefore, trafficking of EGFR regulates signal propagation and amplification (24, 25). Conversely, it has been suggested that signaling can regulate EGFR internalization, as different proteins implicated in signal transduction have been shown to interact with the endocytosis sorting machinery (26, 27). Recently, Zerial's group carried out high-throughput RNA interference analysis to address the role of kinases in endocytosis and showed that a large number of kinases previously implicated in proliferation, growth and cell adhesion also have a role in endocytosis (28).
Anisomycin is an antibiotic isolated from Streptomyces griseolus that inhibits protein synthesis by blocking peptidyl transferase activity in eukaryote ribosomes (29). Anisomycin is a very useful tool because it selectively activates kinase cascades in mammalian cells, especially the MAP kinases (30, 31). In this study, we used anisomycin to activate MAP kinases in the absence of ligand and analyzed the effect of this activation on EGFR internalization. Interestingly, we observed that anisomycin treatment induced EGFR endocytosis and that this process was independent of tyrosine phosphorylation or ubiquitination. Moreover, preincubation of the cells with SB203580, a highly specific inhibitor of p38 (32, 33), or depletion of endogenous p38 by small interfering RNAs (siRNAs) treatment, abolished the anisomycin-induced EGFR internalization suggesting that this MAP kinase plays an important role in the regulation of EGFR trafficking.
To address if the activation of MAP kinases induced by anisomycin has any effect on EGFR internalization, we made use of a chimera in which green fluorescent protein (GFP) has been attached to the carboxyl terminus of human EGFR (EGFR-GFP). This construct allowed us to easily visualize EGFR trafficking by immunofluorescence. It has been previously described that EGFR-GFP biochemical and cellular properties do not differ from EGFR-wt (34). Figure 1A shows that at stationary state, most of EGFR-GFP localized at the plasma membrane confirming that the presence of the GFP did not alter the normal distribution of the protein. Addition of EGF caused a rapid internalization of the receptor to endosomal structures as previously described (35). Interestingly, treatment with anisomycin for short periods of time also induced endocytosis of EGFR-GFP.
In order to characterize the route followed by EGFR-GFP after anisomycin treatment, we analyzed the co-localization of the receptor with different markers. As shown in Figure 1B, we found extensive co-localization of EGFR-GFP with early endosomal markers, such as EEA1 or internalized transferrin, after incubation with the drug for 15 min. In contrast, no co-localization with the late endosomal/lysosomal marker CD63 was observed. Incubation with EGF for 15 min also caused redistribution of EGFR-GFP from the plasma membrane to early endosomes (see Supplementary Material, Figure S1) indicating that both compounds promote trafficking of EGFR-GFP to the same compartments.
Next, we analyzed if anisomycin had the same effect on endogenous EGFR. Control cells or cells treated with anisomycin or EGF for 15 min were fixed, stained with an antibody that recognizes the extracellular domain of EGFR and analyzed by flow cytometry. As shown in Figure 2, treatment with either anisomycin or EGF caused a reduction of approximately 70% in the amount of endogenous EGFR present at the plasma membrane. This indicated that the effect observed by using EGFR-GFP was not a consequence of protein over-expression or mistargeting of the receptor due to the presence of GFP at the cytosolic tail, and validates the use of this chimera.
To address if anisomycin causes the internalization of all cell-surface receptors, we analyzed the effect of the drug on the distribution of Tac, a cell-surface type 1 transmembrane glycoprotein that localizes at the plasma membrane, and TGFβRII, a cell-surface receptor kinase that requires ligand for internalization. As seen in Figure S2 (Supplementary Material), incubation with anisomycin for 20 min caused a robust internalization of EGFR while having no effect on the cell-surface distribution of Tac and TGFβRII. These data show the specifity of anisomycin for EGFR trafficking.
Treatment with anisomycin for short periods of time revealed that there were no apparent changes in the distribution of EGFR-GFP throughout the first 5 min of incubation. However, the receptor appeared at punctate structures following approximately 7 or 8 min of incubation. Many of these punctate structures contained clathrin and the clathrin adaptor AP2 (Figure 3A) suggesting that anisomycin induces EGFR internalization through a clathrin-dependent pathway. To test this possibility, we examined the effect of over-expressing a dominant-negative mutant of dynamin2 (Dyn2-K44A-GFP), a GTPase that is required for the clathrin-dependent internalization of endocytic receptors. As seen in Figure 3B, over-expression of Dyn2-K44A-GFP clearly blocked anisomicyn-induced internalization of EGFR. To further corroborate these data, we reduced the expression of endogenous AP2μ subunit (μ2) by using specific siRNA oligonucleotides. Immunoblot analysis revealed a 92% reduction in the levels of μ2 when compared with cells transfected with control (non-silencing) siRNA. Levels of μ1 and μ3 were monitored as control for the specificity of the antisense (Figure 3C). HeLa cells depleted of µ2 showed very little internalization of transferrin-rhodamine when compared with control cells, indicating that AP2-dependent endocytosis is impaired under our experimental conditions (data not shown). As expected, depletion of µ2 abolished anisomycin-induced internalization of endogenous EGFR indicating that the endocytosis is AP2 dependent (Figure 3D,F). Finally, we analyzed the effect of clathrin siRNA. Figure 3E,F shows that reduction in the levels of clathrin caused a clear decrease in the amount of EGFR that was internalized in response to anisomycin. In contrast, depletion of GGA3, a clathrin adaptor that regulates sorting of proteins at trans Golgi network and endosomes, or treatment with non-silencing siRNA, did not affect EGFR internalization. All together, these data indicate that anisomycin induces endocytosis of EGFR through clathrin-coated pits.
EGF binding induces EGFR dimerization, activation, autophosphorylation of specific tyrosine residues and monoubiquitination of the cytosolic tail. It has been proposed that the recruitment of the endocytic machinery, through interactions with both phosphotyrosines and ubiquitin, plays a role in the regulation of the receptor endocytosis. In Figure 4, we used antibodies against specific phosphotyrosines to follow the activation of the EGFR-GFP after EGF or anisomycin treatment. As mentioned previously, the addition of EGF for 15 min induced a clear redistribution of EGFR-GFP to intracellular vesicles. The majority of these structures was also labeled with antibodies against phophotyrosines 845, 1068 and 1086 indicating that EGFR-GFP is activated. In contrast, incubation with anisomycin caused receptor internalization, but no activation as no staining for phosphorylated tyrosines 845, 1068 or 1086 was observed (Figure 4A). We also generated several mutants in which different residues that are phosphorylated after receptor activation were mutated to alanines, including Y845, Y974, Y1045, Y1068, Y1086 and the double mutant S1046/S1047. Figure S3, Supplementary Material, shows that none of these mutations affected the normal distribution of the EGFR-GFP or its response to anisomycin. In addition, EGFR-GFP immunoprecipitates from HeLa cells treated with EGF or anisomycin were immunoblotted with the anti-phosphotyrosine antibody 4G10 confirming that EGF, but not anisomycin, induced tyrosine phosphorylation of the receptor (Figure 4B). Anisomycin also failed to stimulate ubiquitination of EGFR-GFP as observed by immunoprecipitation followed by immunoblotting with FK2 antibody (Figure 4C). These results indicate that neither phosphotyrosines nor ubiquitin seems to be required for anisomycin-induced EGFR internalization.
Next, we followed the fate of internalized EGFR after anisomycin or EGF treatment. HeLa cells were treated with cycloheximide alone, anisomycin or EGF plus cycloheximide for different periods of time. Western blotting showed that there was a marked down-regulation of EGFR after 2 h of incubation with EGF. In contrast, anisomycin caused a much slower degradation of EGFR (Figure 5A). Quantification of several independent experiments revealed that the differences in the kinetics of EGFR degradation were more evident after short incubation times. For example, EGFR levels dropped a 50% after 1 h of incubation with EGF but showed little change with anisomycin treatment (Figure 5B). Interestingly, treatment with proteosomal inhibitors such as MG132 almost completely abolished anisomycin-induced EGFR degradation but had little effect on EGF-mediated degradation. Conversely, lysosomal inhibitors blocked EGF but not anisomycin-mediated degradation (Figure 5C). These results suggest that anisomycin does not induce delivery of EGFR to lysosomes. Instead, the receptor could cycle between plasma membrane and endosomes until it is degraded most probably through the proteosome, although alternative mechanisms like caspase activation cannot be ruled out (36). Consistent with this idea, we observed a good co-localization between EGFR-GFP and transferrin up to 1 h following EGFR-GFP internalization (data not shown).
It has been reported that anisomycin is a selective activator of the MAP kinases (37, 38). We examined if this activation takes place under our experimental conditions and if it happens quickly enough to justify the early endocytosis observed for EGFR. Total lysates of HeLa cells stimulated with either EGF or anisomycin at different times were analyzed by SDS–PAGE and immunobloted with antibodies against activated p44/42, p38 and JNK. Total p44/42 was monitored as loading control. As previously reported, EGF stimulation induced a rapid activation of three members of the MAP kinase family (Figure 6). Anisomycin was also able to induce phosphorylation of both p38 and JNK. In contrast, anisomycin failed to increase p44/42 activation at early time-points while inducing a very low increase in the levels of phosphorylated p44/42 after 15 min of incubation. Total levels of p38 and JNK protein were not altered by anisomycin treatment (data not shown).
As previously stated, EGFR-GFP appeared in punctated structures that co-localize with clathrin at approximately 7 min after anisomycin addition. This suggests that the protein responsible for the endocytosis of EGFR-GFP is probably activated prior to EGFR-GFP redistribution. The early activation of p38 induced by anisomycin (Figure 6) makes this protein an excellent candidate to play a role in EGFR-GFR internalization. In order to test this possibility, we used a specific inhibitor for p38. Pyridinyl imidazol, SB203580, is a highly specific, cell-permeable inhibitor of p38 (32, 33). This compound has been previously used to determine a role for p38 in several biological processes including UV- and anisomycin-induced c-jun and c-fos expression (37, 39). SB203580 selectively inhibits p38 while having no significant effect on other related kinases such as ERK and JNK. To block the activity of p38, cells were treated with 10 µm SB203580 for 30 min at 37 °C before being exposed to anisomycin for 15 min. As shown in Figure 7A, treatment with SB203580 dramatically decreased the internalization of EGFR-GFP induced by anisomycin, suggesting that p38 activation is necessary for this process. Interestingly, treatment with AG1478, a selective inhibitor of EGFR tyrosine kinase, had no effect on EGFR-GFP endocytosis, further confirming that phosphorylation of EGFR tyrosines is not required for anisomycin-induced EGFR internalization.
Next, we determined if inhibition of p38 by SB203580 had a non-specific effect on clathrin-mediated endocytosis. Figure 7B shows that preincubation with SB203580 blocked anisomycin-induced internalization of EGFR-GFP without affecting transferrin endocytosis. This result indicated that activation of p38 does not play a general role in clathrin-mediated internalization but it is required for down-regulation of specific receptors.
The requirement of p38 MAPK activation for anisomycin-dependent EGFR internalization was further analyzed by flow cytometry. FACS analysis of the EGFR surface expression indicated that preincubation with SB203580 caused a 2.5 fold reduction in the amount of endogenous EGFR internalized after 15 min of anisomycin stimulation (Figure 7C,D). Treatment with dimethyl sulphoxide (DMSO) had no effect on EGFR endocytosis (data not shown).
To corroborate that p38 is required for anisomycin-induced internalization of EGFR, we employed genetic means to selectively deplete endogenous p38. To do so, HeLa cells were transfected either with a pool of siRNAs targeting p38α (siRNA-p38α), p38β (siRNA-p38β) or a combination of both (siRNA-p38α + β). As seen in Figure 8, expression of p38α, but not that of p38β, was abrogated in siRNA-p38α cells, while an inhibition in the expression of p38β, but not p38α, was seen in siRNA-p38β cells. Transfection of siRNA-p38α +β caused a significant reduction in the levels of both p38α and p38β, while treatment with a control non-targeting siRNA did not affect the expression of either of the two isoforms. Interestingly, abrogation of expression of either p38α or p38β reduced the efficiency of EGFR internalization after anisomycin treatment (Figure 8B). This reduction was much more robust in siRNA-p38α + β cells, where only a 10% EGFR internalization was observed after incubation with anisomycin for 15 min. All together, these results indicate that both p38α and p38β might act synergistically in the regulation of EGFR trafficking.
It has been reported that UV radiation can induce internalization of EGFR independent of its phosphorylation or RTK activation. The mechanism that mediates this process has not been characterized although it has been suggested that direct absorption of UV energy might induce a conformational change of EGFR (40, 41). The fact that p38 can be activated by a variety of stress signals, including UV radiation, suggested that this protein could be involved in the UV-induced internalization of EGFR. Figure 9 shows that after UV radiation (200 J/m2) an extensive EGFR-GFP internalization, comparable with that seen after EGF or anisomycin stimulation, was observed. As expected, addition of SB203580 to the cells 30 min prior to UV radiation inhibited EGFR-GFP internalization which confirmed our hypothesis that p38 plays an important role in UV-induced endocytosis of EGFR.
We have shown that activation of the stress-induced p38 MAP kinase by anisomycin induces a rapid internalization of EGFR. Interestingly, EGFR endocytosis was independent of RTK activity and monoubiquitination of the cytosolic tail indicating that EGF and anisomycin employ different mechanisms to promote internalization. The lack of ubiquitination prevented the delivery of EGFR to lysosomes for degradation. This observation is in agreement with recent reports that found that ubiquitination of EGFR is required for interaction with the mutivesicular bodies-sorting machinery (42, 43).
p38 was originally identified as a kinase phosphorylated in response to endocytic lipopolysacharides (44, 45). Later, it was found that p38 activity is also up-regulated when cells are exposed to a variety of stimuli including certain growth factors, proinflammatory cytokines (46–48) and different forms of environmental stress such as UV light (35, 49), heat (32) and osmotic shock (32, 45, 46). To date, four members of the p38 group of MAP kinases have been characterized, including p38α (50), p38β (51), p38γ (52, 53) and p38δ (51). SB203580 is a selective inhibitor for both, p38α and β, but has no effect on the activity of the γ and δ isoforms. The inhibition of the anisomycin-induced EGFR internalization observed in the presence of SB203580 strongly suggests the involvement of p38α and/or p38β in this process. The additive effect of p38α and p38β silencing on EGFR internalization after anisomycin treatment corroborate that both isoforms likely play an important role in the regulation of EGFR trafficking. It is important to note that, while inhibition of p38 activation clearly prevented EGFR entry into the cells, no effect on transferrin internalization was observed, indicating that SB203580 does not cause a general block of clathrin-mediated endocytosis.
Recently, it has been shown that exposure of cells to UV radiation also induces internalization of EGFR (40), but the precise mechanism that controls this process remains unknown. Significantly, there are several similarities between UV-induced and anisomycin-induced EGFR endocytosis. For example, in both cases, EGFR internalization is processed by clathrin-coated pits, is independent of RTK activity or autophosphorylation, does not require receptor ubiquitination and does not result in lysosomal degradation of the receptor (41, 54, 36). In this paper, we show that activation of p38 is involved in the UV-induced internalization of EGFR, suggesting that the regulation of EGFR endocytosis by p38 can occur under physiological conditions. It has been shown that EGFR is involved in cell proliferation, survival and tumorogenesis and that preventing EGFR down-regulation facilitates cell transformation. Therefore, external stimuli that cause p38 activation could control the accessibility of EGFR at the plasma membrane preventing that way cell proliferation and survival under stress conditions.
How does p38 promote the internalization of EGFR? There is growing evidence showing that p38 plays an important role in numerous biological processes including inflammation (55, 56), development (57, 58), cell death (59, 60), cell cycle (61), cardiomyocyte hypertrophy (62), cell differentiation (63, 64), senescence (65) and tumorogenesis (66). Recently, it has been suggested that p38 might also participate in the regulation of endocytic trafficking. Cavalli et al. (2001) (67) have reported that p38 can phosphorylate and activate guanyl-nucleotide dissociation inhibitor (GDI), a key regulator of the Rab cycle. Rab proteins are small monomeric GTPases with molecular masses in the 20–30 kDa range (68). Multiple Rabs have been shown to participate in the formation, fusion and movement of vesicular traffic intermediaries between different membrane compartments of the cell. Rabs function as molecular switches by cycling between two interconvertible forms, a cytosolic GDP-bound (inactive) form and a membrane associated GTP-bound (active) form. In addition, Rabs also cycle between membrane-bound and cytosolic states, and this cycling is regulated by GDI (69).
Rab 5 in particular seems to play an important role in the trafficking of EGFR. Several studies have established that activated EGFR modulates the GTPase activity of Rab5 by targeting either GTPase-activating proteins, such as RN-Tre (70), or GTP exchange factors, such as RIN1 (71). The activation of Rab5 through EGFR or the expression of constitutively active mutants of Rab5 stimulates both the internalization and degradation of activated EGFR. In contrast, dominant negative Rab5 blocks EGF-stimulated receptor-mediated and fluid-phase endocytosis (72). Therefore, p38 could promote EGFR endocytosis by stimulating the activity of GDI in extracting Rab5 from the endosomal membranes and forming cytosolic GDI-Rab5 complex. Interestingly, GDI-Rab5 has been identified as a component of the machinery controlling clathrin-coated endocytic vesicle formation (73). In addition, GDI might facilitate the delivery of Rab5 to specific regions of the plasma membrane facilitating the interaction with cytoskeleton or specific effectors. In agreement with this idea, Huang et al. (74) have shown that the activation of p38 induced by metabotropic glutamate receptor agonists accelerates loss of surface amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors by stimulating the formation of GDI-Rab5 complexes.
We cannot discard the possibility that activation of p38 could also affect EGFR recycling. Recent evidence suggests that p38 can be recruited to endosomes (28) and regulates endosomal Rab5 effectors such as EEA1 (75). p38 also seems to play a negative regulatory role in Mycobacterium tuberculosis infection by modulating the recruitment of EEA1 to phagosomes and inhibiting that way phagosome maturation (76). This involvement may reflect a more general role for p38 in the regulation of intracellular trafficking. While further studies will be required to assess the specific mechanisms used by p38 to regulate EGFR internalization, our results strengthen the idea that there is a clear intercommunication between signaling and intracellular trafficking and suggest that p38 is a key player in this process.
The following commercial antibodies were used: mouse monoclonal anti-ubiquitin (FK2; Affiniti, Devon, UK), mouse monoclonal anti-EEA1, mouse monoclonal anti-CHC and mouse monoclonal anti-GGA3 (BD Transduction Laboratories, San Jose, CA, USA), mouse monoclonal anti-human TGFβRII (R&D Systems Inc., Minneapolis, MN, USA), mouse monoclonal to α-adaptin (AP-6; Affinity Bioreagents, Golden, CO, USA), mouse monoclonal anti-CD63 (H5C6; BD Pharmigen, San Jose, CA, USA), mouse phosphotyrosine antibody (clone 4G10; Upstate Biotechnology, Lake Placid, NY, USA), rabbit anti-GFP (MBL International, Woburn, MA, USA), mouse monoclonal and rat monoclonal anti-EGF receptor (ab3103 and ICR10; Abcam, Cambridge, MA, USA). Rabbit polyclonal antibodies against p38, phospho-p38, p44/42, phospho-p44/42, phospho-JNK, EGF-receptor, phospho-EGF receptor (Tyr845), phospho-EGF receptor (Tyr1068) and phospho-EGF receptor (Tyr1086) were obtained from Cell Signaling Technology (Beverly, MA, USA). Rabbit polyclonal antibodies to µ1, µ2 and µ3 were the kind gift of JS. Bonifacino (NIH, Bethesda, MD, USA).
Anisomycin, EGF, SB203580, AG1478, MG132, bafilomycin A1, ubiquitin aldehyde, mammalian phosphatase inhibitor cocktail and NP40 were obtained from Sigma (St. Louis, MO, USA). Rhodamine-transferrin was supplied by Molecular Probes (Eugene, OR, USA).
Cloning and characterization of the EGFR-GFP chimera has been previously described (34). Mutations of residues in the cytosolic tail of EGFR-GFP were introduced using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). The GFP-tagged dynamin2 K44A construct was a gift from M. McNiven (Mayo Clinic, Rochester, MN, USA).
RNAi of CHC, GGA3 and the µ subunit of the AP2 complex was performed using siRNAs to the following human target sequences: UAAUCCAAUUCGAAGACCAAUU for CHC, GUGGAUGCCUUUCGGGUCA for µ2 and AAAAACGGCUUCCGCAUCCUC for GGA3 (Dharmacon Research, Lafayette, CO). Heterogeneous duplex siRNA pool against p38 MAP kinase and p38 MAP kinase β were obtained from Cell Signaling Technology and Dharmacon, respectively. For each siRNA, two consecutive transfections every 72 h were carried out in HeLa cells according to the manufacturer's instructions.
HeLa cells were transfected with a plasmid encoding EGFR-GFP by using FuGENE-6 (Roche Diagnostics, Indianapolis, IN, USA). For immunofluorescence, transfected HeLa cells were grown on coverslips. Twenty-four hours after transfection, the cells were maintained in serum-free medium for 6–8 h, stimulated with EGF (100 ng/mL) or anisomycin (60 µm) for 15 min and fixed in methanol/acetone (1:1, v/v) for 10 min at −20 °C. Coverslips were mounted onto glass slides with Fluoromount G (Southern Biotechnology Associates, Birmingham, AL, USA). Fluorescence images were acquired on an LSM 510 confocal microscope (Carl Zeiss, Thornwood, NY, USA).
To examine the co-localization of EGFR-GFP with endosomal markers, incubation with primary antibodies diluted in PBS, 0.1% (wt/vol) saponin and 0.1% BSA, was carried out for 1 h at room temperature. Unbound antibodies were removed by rinsing with PBS for 5 min, and cells were subsequently incubated with a secondary antibody (Cy3-conjugated donkey anti-rabbit or anti-mouse Ig) diluted in PBS, 0.1% (wt/vol) saponin and 0.1% BSA, for 30–60 min at room temperature. After a final rinse with PBS, coverslips were mounted onto glass slides with Fluoromount G and analyzed by confocal microscopy.
Treatments with SB203580 or AG1478 were carried out by incubation of the cells with the inhibitors for 30 min prior to anisomycin stimulation. Cells were exposed to UV radiation in a UV Stratalinker 2400 (Stratagene).
HeLa cells were starved for 8 h in serum-free medium and then stimulated with EGF (100 ng/mL) or anisomycin (60 µm) for 15 min. The cells were then washed with ice-cold PBS and lysed for 15 min in lysis buffer (25 mm Tris–Cl, pH 7.4, 150 mm NaCl, 5 mm ethylenediaminetetraacetic acid, 20 mm NaF, 0.5% NP40) supplemented with protease, tyrosine phosphatase and ubiquitin hydrolase inhibitors. The lysate was precleared by centrifugation and incubated with 5 µL of anti-GFP or a non-specific antibody and protein G-Sepharose (Amersham Biosciences, Piscataway, NJ). Immunoprecipitates were collected, washed six times with 1 mL of lysis buffer supplemented with phosphatase inhibitors and analyzed by SDS–PAGE under reducing conditions.
Immunoblotting was carried out according to standard procedures. Proteins were separated by SDS–PAGE and transferred to nitrocellulose. The membrane was then blocked with PBS/0.05% Tween-20/10% BSA and incubated with the various antibodies. Enhanced chemiluminescence reagent (Amersham Biosciences) was used for detection.
HeLa cells were serum starved for 8 h and stimulated with EGF (100 ng/mL) or anisomycin (60 µm) for the indicated times. For degradation assays, total cell lysates were subjected to immunoblotting with antibodies against EGFR. The amounts of EGFR were quantified at each time-point by using the public domain NIH Image program (1.6–2) and are represented as the percentage of remaining EGFR in comparison with unstimulated cells in the same experiment. The activation of p44/42, JNK and p38 was determined by Western blotting with antibodies specific for phosphorylated, activated forms of these kinases.
HeLa cells were grown to 90% confluence. Following serum starvation for 4–5 h, the cells were harvested in Cellstripper™ solution (Mediatech, Inc., Herdon, VA), washed once with cold PBS and incubated with DMSO or SB203580 (10 μM) at 4 °C for 30 min. The cells were then incubated with EGF (100 ng/mL) or anisomycin (10 µm) for the indicated times at 37 °C, and then placed on ice to stop internalization. The cells were fixed with 2% paraformaldehyde, incubated with the FITC-conjugated anti-EGFR antibody for 45 min on ice, washed and analyzed by the FACS-Calibur using cellquest software (BD Bioscience, San Jose, CA). Amounts of EGFR remaining on the cell surface were defined as the specific fluorescence value, which was calculated after subtracting background (fluorescence of non-stained cells). Percent internalization was calculated where the specific mean fluorescence value of cells incubated at 37 °C with SB203580 was treated as 100%.
We thank C. Mullins for critical reading of the manuscript. We also appreciate the editorial assistance of the NCI, CCR Fellows Editorial Board. This project was supported by the Intramural Research Program of the NIH, National Heart, Lung, and Blood Institute (NHLBI).
EGFR-GFP redistributes from the plasma membrane to early endosomes after EGF stimulation. HeLa cells were transfected with a plasmid encoding EGFR-GFP. Transfected cells were incubated with EGF (100 ng/mL) for 15 min, fixed, permeabilized, immunostained with the indicated antibodies and examined by confocal fluorescence microscopy. For transferrin staining, cells were incubated with rhodamine-transferrin for 15 min at 37 °C. EGFR-GFP is in green; EEA1, transferrin and CD63 are in red and yellow indicates co-localization. Scale bar represents 10 µm.
Anisomycin has no effect on the distribution of Tac and TGFβRII. (A) HeLa cells expressing EGFR-GFP or Tac were left untreated or stimulated with anisomycin for 20 min. Cells were then fixed and analyzed by confocal microscopy. Bar represents 10 µm. (B) Cell surface levels of EGFR or TGFβRII were quantified by flow cytometry in unstimulated cells or cells exposed to anisomycin for 20 min. For detection of TGFβRII, HeLa cells were transiently transfected with a plasmid encoding human TGFβRII.
Anisomycin-induced internalization of EGFR-GFP was not affected by mutation of specific carboxy-terminal tyrosine residues to alanines. Wild-type EGFR-GFP or EGFR-GFP carrying the indicated mutations were transiently expressed in HeLa cells. Twenty-four hours after transfection, cells were either left untreated, or incubated with anisomycin for 15 min, fixed and analyzed by confocal microscopy. Scale bar represents 10 µm.